The binding of extracellular S100A4 to embigin mediates prostate cancer progression by orchestrating multiple mechanisms including inhibition of AMPK activity, activation of NF-κB, MMP9, and mTORC1 signaling, and inhibition of autophagy, which lead to an increase in cellular motility. Here, EMB is linked to prostate carcinoma.